AMN Healthcare Q3 revenue beats estimates, partly driven by strong show in nurse and allied solutions segment

Reuters11-07
<a href="https://laohu8.com/S/AMN">AMN Healthcare</a> Q3 revenue beats estimates, partly driven by strong show in nurse and allied solutions segment

Overview

  • AMN Healthcare Q3 revenue of $634 mln beats analyst expectations despite 8% yr/yr decline

  • Adjusted EPS of $0.39 for Q3 beats analyst expectations, down 36% yr/yr

  • Company refinanced senior notes and extended credit facility, enhancing financial flexibility

Outlook

  • Company expects Q4 revenue between $715 mln and $730 mln

  • Nurse and Allied Solutions revenue expected to rise 1-3% year-over-year

  • Technology and Workforce Solutions revenue projected to decline 14-16% year-over-year

Result Drivers

  • REVENUE GUIDANCE EXCEEDED - Co's Nurse and Allied Solutions and Physician and Leadership Solutions segments performed better than expectations, contributing to revenue exceeding guidance

  • SG&A MANAGEMENT - Effective management of SG&A expenses resulted in a higher-than-expected adjusted EBITDA margin

  • STAFFING ORDERS REBOUND - Co reports a rebound in staffing orders and higher winter order volume

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$634.50 mln

$618.10 mln (9 Analysts)

Q3 Adjusted EPS

Beat

$0.39

$0.21 (8 Analysts)

Q3 EPS

$0.76

Q3 Net Income

$29.30 mln

Q3 Gross Margin

29.10%

Q3 Operating margin

7.50%

Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 5 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy."

  • Wall Street's median 12-month price target for AMN Healthcare Services Inc is $21.00, about 1.8% above its November 5 closing price of $20.63

  • The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release: ID:nGNX9PKX1f

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment